Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Perioper Med (Lond) ; 6: 13, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28948012

RESUMO

BACKGROUND: While enhanced recovery protocols (ERPs) reduce physiologic stress and improve outcomes in general, their effects on postoperative renal function have not been directly studied. METHODS: Patients undergoing major colorectal surgery under ERP (February 2010 to March 2013) were compared with a traditional care control group (October 2004 October 2007) at a single institution. Multivariable regression models examined the association of ERP with postoperative creatinine changes and incidence of postoperative acute kidney dysfunction (based on the Risk, Injury, Failure, Loss, and End-stage renal disease criteria). RESULTS: Included were 1054 patients: 590 patients underwent surgery with ERP and 464 patients without ERP. Patient demographics were not significantly different. Higher rates of neoplastic and inflammatory bowel disease surgical indications were found in the ERP group (81 vs. 74%, p = 0.045). Patients in the ERP group had more comorbidities (ASA ≥ 3) (62 vs. 40%, p < 0.001). In unadjusted analysis, postoperative creatinine increase was slightly higher in the ERP group compared with control (median 0.1 vs. 0 mg/dL, p < 0.001), but levels of postoperative acute kidney injury were similar in both groups (p = 0.998). After adjustment with multivariable regression, postoperative changes in creatinine were similar in ERP vs. control (p = 0.25). CONCLUSIONS: ERP in colorectal surgery is not associated with a clinically significant increase in postoperative creatinine or incidence of postoperative kidney injury. Our results support the safety of ERPs in colorectal surgery and may promote expanding implementation of these protocols. TRIAL REGISTRATION: Not applicable, prospective data collection and retrospective chart review only.

3.
Neurochem Res ; 37(6): 1137-49, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22237969

RESUMO

The neutral sphingomyelinases (N-SMases) are a group of Mg²âº-dependent enzymes with a pH optimum in the neutral range. N-SMases catalyze the conversion of sphingomyelin to ceramide and have been found particularly enriched in brain tissue. N-SMase activity has been implicated in many physiological and pathological processes affecting the brain and nervous system. In this review, we discuss the proposed functions of N-SMase with a particular emphasis on its role in neurological disorders, such as age-related neurodegeneration, Alzheimer's disease, HIV-associated dementia, atherosclerosis, ischemia-reperfusion injury, and cancer.


Assuntos
Doenças Neurodegenerativas/enzimologia , Esfingomielina Fosfodiesterase/fisiologia , Arterite do Sistema Nervoso Central Associada a AIDS/fisiopatologia , Envelhecimento , Doença de Alzheimer/patologia , Doença de Alzheimer/fisiopatologia , Animais , Apoptose/fisiologia , Aterosclerose/complicações , Química Encefálica , Ceramidas/metabolismo , Encefalite/complicações , Humanos , Concentração de Íons de Hidrogênio , Magnésio/farmacologia , Camundongos , Camundongos Knockout , Neoplasias/fisiopatologia , Doenças Neurodegenerativas/fisiopatologia , Ratos , Traumatismo por Reperfusão/etiologia , Transdução de Sinais/fisiologia , Esfingolipídeos/metabolismo , Esfingomielina Fosfodiesterase/antagonistas & inibidores , Tromboembolia/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...